Ellie G😷

Sparsentan for FSGS?? It's alive....
ir.travere.com/press-releas...

T3b: Obinutuzumab achieved sustained B-cell depletion (CD19+ <10/µL) in 95% of patients through week 76, outperforming Rituximab (~80% at week 52, LUNAR trial).
pubmed.ncbi.nlm.nih....

Obvious question: why REGENCY was positive and LUNAR negative? #nephJC

T2e: With obinutuzumab there was a greater reduction in protein-to-creatinine ratio (adjusted difference 13.7%) #NephJC

Proteinuric response (UPCR <0.8 g per gram) without intercurrent events was significantly higher in the obinutuzumab arm (55.5% vs 41.9%)

Obinutuzumab in Lupus Nephritis — NephJC This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not ...

Tonite at 9pm, only on #Blusky, we discuss the new kid on the block for lupus nephritis! Join us for nephrology education as we close in on #WorldKidneyDay #NephSky
Obinutuzumab, a super B-Cell destroyer 💥
www.nephjc.com/news/regency...

Rituximab-induced serum sickness (RISS) is a rare drug complication in patients w/steroid-dependent nephrotic syndrome (SDNS). Read these Clinical Insights on low-dose obinutuzumab for SDNS complicated by recurrent RISS & anti-rituximab antibodies.
link.springer.com/article/10.1...

New coronavirus discovered in Chinese bats sparks alarm The virus binds to humans in a similar way to the virus that causes COVID-19.

www.newsweek.com/new-coronavi...

A new horizon in #FSGS coming soon?

Earlier this week, Travere Therapeutics announced plans to submit an sNDA for sparsentan (Filspari) based on DUPLEX trial and PARASOL data.

#Nephrology #FDANews

www.hcplive.com/view...

Effects of GLP-1 Receptor Agonists on Kidney and Cardiovascular Outcomes | Docwire News A study examined whether GLP-1 receptor agonists improved clinically important kidney outcomes and whether patients without diabetes could benefit from treatment with them.

A study sought to shed light on whether GLP-1 receptor agonists reduce the risk of significant kidney outcomes and whether they have #kidney and #cardiovascular benefits for patients without #diabetes. #nephrology #nephsky #glp1ra

Background for NOBILITY trial

Obinituzumab properties

Next up is Brad Rovin on the REGENCY trial of obinituzumab in lupus nephritis

Background - more potent B cell depletion than Rituximab

Humanized
Less reliance on complement mediated
#ISNWCN #NephSky

FLOW study in @nejm.org. MOA for renal protection with SEM likely multi factorial but independent of weight/glycemic control. #GLP1 RA’s reduce glomerular inflammation (⬇️ IL6), reduce fibrosis (⬇️ TGFb), & reduce vascular oxidative stress (⬆️NO, ⬇️ RAS). #RheumSky #NephSky #CardioMetabolic

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

BREAKING NEWS: The FDA has approved Ozempic for patients with chronic kidney disease. This means the popular injection can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.

Ozempic now FDA approved for CKD!

Kidney Function Decline After COVID-19 Infection This cohort study examines the annual decrease in estimated glomerular filtration rates among adults diagnosed with COVID-19 and pneumonia in Stockholm, Sweden.

Time to add prior COVID infection to your CKD review of systems?

jamanetwork.com/journals/jam...

Obinutuzumab Efficacy, Safety for FSGS Treatment | Docwire News Obinutuzumab reduced proteinuria in patients with focal segmental glomerulosclerosis (FSGS) who were treatment-resistant or dependent on immunosuppressive therapy.

A study examined the efficacy and safety of obinutuzumab to treat patients with focal segmental glomerulosclerosis who were treatment-resistant or dependent on immunosuppressive therapy. #nephrology #nephsky #KidneyWk #FSGS #kidneydisease

🚀Mobilising advances in rare kidney disease🚀

The National Registry of Rare Kidney Diseases is a powerful data source helping to improve our understanding of rare kidney conditions & supporting clinical trials.

🔬Find out more about Radar: ukkidney.org/rare-renal/h...

ACR Issues Summary of New Lupus Nephritis Guidance | Docwire News The American College of Rheumatology issued a summary of a new guideline for the screening, treatment, and management of lupus nephritis that will be published in 2025.

📣 Have you heard? The American College of Rheumatology has issued a summary of a new guideline for lupus nephritis. #rheumatology #nephrology #nephsky #lupusnephritis

Optimal rituximab dosing when given w/mycophenolate mofetil (MMF) for frequently relapsing nephrotic syndrome/steroid-dependent nephrotic syndrome remains uncertain. Read this Original Article comparing single vs. double dose of rituximab w/MMF.
link.springer.com/article/10.1...

Association Between Inflammatory Skin Diseases and IgA Nephropathy | Docwire News A study examined a possible link between IgA nephropathy (IgAN) and inflammatory skin diseases, such as atopic dermatitis, acne, and psoriasis.

The study used bidirectional Mendelian randomization to examine causality between inflammatory skin diseases and #IgAN. #nephrology #skindisease #iganephropathy #nephsky

We've kicked off the first-ever #rFSGSConference! We look forward to an impactful day by and for #rFSGS patients. #RareDisease #KidneyTransplant

Combination induction immunosuppression with rituximab, cyclophosphamide, and prednisone for fibrillary glomerulonephritis
#nephsky
www.kireports.org/article/S246...

I wish I could say I was surprised 😢

My thoughts exactly.

Model of the novel coronavirus

I’m thrilled that our project investigating public understandings of immunity systems and human-microbial relations has been funded by the Australian Research Council

🆕 Antibody identified in podocytopathies 🫘after Anti nephrin Ab⭐

Anti Slit diaphragm Ab ‼️‼️‼️

The heterogeneity in response to immunosuppression is understandable now!
#Nephsky

Would love more research in this area for other autoimmune diseases such as primary FSGS. It seems promising for many.

A new definition of Long COVID New research and a formal definition of Long COVID from the National Academies of Sciences, Engineering, and Medicine can guide psychologists in helping patients battling the condition

“Long COVID is not a psychological condition. It is a medical condition, and it should be treated as such”

Psychologizing people with Long Covid is dangerous. It prevents them from getting the care they need.

Once they understand it’s a severe medical condition - they MAY mask up avoid reinfection

Struggling today. Really hard to hear that extended family would prefer I not attend Christmas than any of them take any precautions prior to make it safe. I feel like since my diagnosis, some family have already decided I’m gone.
#chronicillness #autoimmunedisease
#primaryfsgs

Those who oppose Covid mitigations say it’s because we won’t stop until we reinstate lockdowns

Many disabled people have been locked down for 5 years. All we want is safe access to public spaces

Just give us clean air, paid sick time & masks in high risk public spaces.

It doesn’t have to be hard.

Toxic positivity in disability justice manifests as nondisabled people demanding we:

-not discuss the reality of our disability
-temper our language to soften our truths
-focus only on “inspiring” messages
-ignore the ongoing impact of ableism in favor of reaching nondisabled people

Quite amazing. I’m wondering if this could help those with Primary FSGS?